- ►annals.org [PDF] KJ Pandya, RF Raubertas, PJ Flynn, HE Hynes … - Annals of internal medicine, 2000 - Am Coll Physicians Kishan J. Pandya, MD; Richard F. Raubertas, PhD; Patrick J. Flynn, MD; Harry E.
Hynes, MD; Richard J. Rosenbluth, MD; Jeffrey J. Kirshner, MD; H. Irving Pierce,
MD; Vladimir Dragalin, PhD; and Gary R. Morrow, PhD, MS Cited by 185 - Related articles - BL Direct - All 5 versions
RM Goldberg, CL Loprinzi, JR O'fallon, MH … - Journal of clinical oncology: official journal of the …, 1994 - ncbi.nlm.nih.gov PURPOSE: To determine the efficacy of transdermal clonidine for alleviating
tamoxifen-induced hot flashes in women with a history of breast cancer. PATIENTS
AND METHODS: A randomized, double-blind, crossover design was used in this ... Cited by 191 - Related articles - BL Direct - All 3 versions
T Guttuso Jr, R Kurlan, MP McDermott, K … - Obstetrics & Gynecology, 2003 - journals.lww.com RESULTS: After 12 weeks of double-blind treatment, inten- tion-to-treat analysis
showed that gabapentin 900 mg per day was associated with a 45% reduction in hot
flash frequency and a 54% reduction in hot flash composite score (frequency ... Cited by 190 - Related articles - All 7 versions
- ►vcu.edu [PDF] CL Loprinzi, JW Kugler, JA Sloan, JA … - The Lancet, 2000 - Elsevier Participants were assigned placebo (n=56) or venlafaxine 37ยท5 mg daily (n=56),
75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week,
patients took the study medication for 4 weeks. All venlafaxine treatment ... Cited by 469 - Related articles - BL Direct - All 6 versions
- ►jcojournal.org CL Loprinzi, JA Sloan, EA Perez, SK Quella, … - Journal of Clinical Oncology, 2002 - jcojournal.org PATIENTS AND METHODS: This trial used a double-blinded, randomized, two-period
(4 weeks per period), cross-over methodology to study the efficacy of fluoxetine
(20 mg/d) for treating hot flashes in women with a history of breast cancer ... Cited by 333 - Related articles - BL Direct - All 8 versions
- ►ascopubs.org [PDF] DL Barton, CL Loprinzi, SK Quella, JA Sloan, … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org Purpose: Hot flashes represent a substantial clinical problem for some breast
cancer survivors. Although estrogen or progesterone preparations can alleviate
these symptoms in many patients, concern remains regarding the use of ... Cited by 271 - Related articles - BL Direct - All 8 versions
CL Loprinzi, JC Michalak, SK Quella, JR O' … - New England Journal of Medicine, 1994 - content.nejm.org Methods The patients included 97 women with a history of breast cancer and 66
men with prostate cancer who had undergone androgen-deprivation therapy. All
patients had experienced bothersome hot flashes (median number per day at ... Cited by 381 - Related articles - BL Direct - All 6 versions
V Stearns, KL Beebe, M Iyengar, E Dube - Jama, 2003 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Standard therapy ... Cited by 342 - Related articles - BL Direct - All 9 versions
- ►nih.gov KJ Pandya, GR Morrow, JA Roscoe, H Zhao, JT … - The Lancet, 2005 - Elsevier Evaluable data were available on 371 participants at 4 weeks (119 placebo, 123
gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at 8 weeks (113 placebo,
114 gabapentin 300 mg, and 120 gabapentin 900 mg). The percentage decreases ... Cited by 115 - Related articles - BL Direct - All 16 versions
ML Evans, E Pritts, E Vittinghoff, K McClish, … - Obstetrics & Gynecology, 2005 - journals.lww.com Michele L. Evans, MD, Elizabeth Pritts, MD, Eric Vittinghoff, PhD, MPH, Karen
McClish, Kevin S. Morgan, and Robert B. Jaffe, MD ... OBJECTIVE: To examine the
efficacy of extended-release ven- lafaxine for the treatment of ... Cited by 119 - Related articles - All 4 versions
